Background/Aims: Non-fatal opioid overdose (NFOO) and major depression (MD) are highly prevalent in heroin users. Many risk factors are known for NFOO, but studies in non-clinical samples on its relationship with MD are lacking. We aimed to examine this relationship in a street-recruited sample, controlling for potential well-known confounders. Methods: A cross-sectional study in 452 heroin users street-recruited by chain referral methods in three Spanish cities. Eligibility criteria were: age ≤30 years, heroin use at least 12 days in the last year and at least once in the last 3 months. Depression was assessed using the Composite International Diagnostic Interview. A precise definition of NFOO was used. Adjusted odds ratios (AORs) for the NFOO predictors were obtained by logistic regression. Results: The prevalence of NFOO and MD in the last 12 months was 9.1 and 23.2%, respectively. After adjusting for potential confounders, NFOO and MD were significantly associated (AOR 2.2; 95% CI 1.01-4.74). Other associated factors were imprisonment (AOR 4.1; 95% CI 1.4-12.1), drug injection (AOR 6.7; 95% CI 2.4-18.4) and regular use of tranquillisers/sleeping pills (AOR 2.9; 95% CI 1.16-7). Conclusions: Drug and mental health treatment facilities should consider the relationship between MD and NFOO when contacting and treating heroin users. Imprisonment, drug injection and use of tranquillisers/sleeping pills are also risk factors for NFOO.

Keywords:
Non-fatal opioid overdose, Major depression, Heroin users , Epidemiology
1.
EMCDDA: Annual report 2012: Annual report on the state of the drugs problem in Europe. Luxembourg, Office for Official Publications of the European Communities/European Monitoring Center for Drugs and Drug Addiction (EMCDDA), 2012.
2.
Darke S, Mattick RP, Degenhardt L: The ratio of non-fatal to fatal heroin overdose. Addiction 2003;98:1169-1171.
3.
Harris EC, Barraclough B: Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997;170:205-228.
4.
Darke S, Hall W: Heroin overdose: research and evidence-based intervention. J Urban Health 2003;80:189-200.
5.
Ochoa KC, Davidson PJ, Evans JL, Hahn JA, Page-Shafer K, Moss AR: Heroin overdose among young injection drug users in San Francisco. Drug Alcohol Depend 2005;80:297-302.
6.
Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE: Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 1997;54:71-80.
7.
Havard A, Teesson M, Darke S, Ross J: Depression among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS). J Subst Abuse Treat 2006;30:355-362.
8.
Brugal MT, Barrio G, De la Fuente L, Regidor E, Royuela L, Suelves JM: Factors associated with non-fatal heroin overdose: assessing the effect of frequency and route of heroin administration. Addiction 2002;97:319-327.
9.
Kerr T, Fairbairn N, Tyndall M, Marsh D, Li K, Montaner J, Wood E: Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend 2007;87:39-45.
10.
Tobin KE, Latkin CA: The relationship between depressive symptoms and nonfatal overdose among a sample of drug users in Baltimore, Maryland. J Urban Health 2003;80:220-229.
11.
Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, Turner BJ, Eggan F, Beckman R, Vitiello B, Morton SC, Orlando M, Bozzette SA, Ortiz-Barron L, Shapiro M: Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001;58:721-728.
12.
Stewart D, Gossop M, Marsden J: Reductions in non-fatal overdose after drug misuse treatment: results from the National Treatment Outcome Research Study (NTORS). J Subst Abuse Treat 2002;22:1-9.
13.
Darke S, Ross J, Hall W: Overdose among heroin users in Sydney, Australia. I. Prevalence and correlates of non-fatal overdose. Addiction 1996;91:405-411.
14.
Brugal MT, Domingo-Salvany A, Puig R, Barrio G, Garcia de Olalla P, De la Fuente L: Evaluating the impact of methadone maintenance programmes on mortality due to overdose and AIDS in a cohort of heroin users in Spain. Addiction 2005;100:981-989.
15.
Dean AJ, Bell J, Christie MJ, Mattick RP: Depressive symptoms during buprenorphine versus methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry 2004;19:510-513.
16.
Wines JD Jr, Saitz R, Horton NJ, Lloyd-Travaglini C, Samet JH: Overdose after detoxification: a prospective study. Drug Alcohol Depend 2007;89:161-169.
17.
Maloney E, Degenhardt L, Darke S, Nelson EC: Are non-fatal opioid overdoses misclassified suicide attempts? Comparing the associated correlates. Addict Behav 2009;34:723-729.
18.
Darke S, Mills K, Teesson M, Ross J, Williamson A, Havard A: Patterns of major depression and drug-related problems amongst heroin users across 36 months. Psychiatry Res 2009;166:7-14.
19.
Burns JM, Martyres RF, Clode D, Boldero JM: Overdose in young people using heroin: associations with mental health, prescription drug use and personal circumstances. Med J Aust 2004;181:S25-S28.
20.
Watters JK, Biernacki P: Targeted sampling: options for the study of hidden populations. Soc Probl 1989;36:416-430.
21.
Heckathorn DD: Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl 1997;44:174-199.
22.
De la Fuente L, Brugal MT, Ballesta R, Bravo MJ, Barrio G, Domingo-Salvany A, Silva RT, Ambros M: Cohort study methodology of the ITINERE Project on heroin users in three Spanish cities and main characteristics of the participants (in Spanish). Rev Esp Salud Publica 2005;79:475-491.
23.
Kessler RC, Ustun TB: The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res 2004;13:93-121.
24.
Haro JM, Arbabzadeh-Bouchez S, Brugha TS, de Girolami G, Guyer ME, Jin R, Lepine JP, Mazzi F, Reneses B, Vilagut G, Sampson NA, Kessler RC: Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys. Int J Methods Psychiatr Res 2006;15:167-180.
25.
Jones JD, Mogali S, Comer SD: Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend 2012;125:8-18.
26.
Green TC, McGowan SK, Yokell MA, Pouget ER, Rich JD: HIV infection and risk of overdose: a systematic review and meta-analysis. AIDS 2012;26:403-417.
27.
Milloy MJ, Kerr T, Tyndall M, Montaner J, Wood E: Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. PLoS One 2008;3:e3351.
28.
Neale J: Suicidal intent in non-fatal illicit drug overdose. Addiction 2000;95:85-93.
29.
Rossow I, Lauritzen G: Balancing on the edge of death: suicide attempts and life-threatening overdoses among drug addicts. Addiction 1999;94:209-219.
30.
Best D, Gossop M, Man L-H, Finch E, Greenwood J, Strang J: Accidental and deliberate overdose among opiate addicts in methadone maintenance treatment: are deliberate overdose systematically different? Drug Alchohol Rev 2000;19:213-216.
31.
Doe-Simkins M, Walley AY, Epstein A, Moyer P: Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health 2009;99:788-791.
32.
Merrall EL, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J, Hutchinson SJ, Bird SM: Meta-analysis of drug-related deaths soon after release from prison. Addiction 2010;105:1545-1554.
33.
World Health Organization: Prevention of acute drug-related mortality in prison populations during the immediate post-release period. Copenhagen, WHO Regional Office for Europe, 2010.
34.
McGregor C, Darke S, Ali R, Christie P: Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions. Addiction 1998;93:701-711.
35.
Pani PP, Maremmani I, Pacini M, Lamanna F, Maremmani AG, Dell'osso L: Effect of psychiatric severity on the outcome of methadone maintenance treatment. Eur Addict Res 2011;17:80-89.
36.
Colom FJ, Casas M, Perez de Los CJ, Del RM, Roncero C, Castells X, Valero S, Eiroa-Orosa FJ, Batlle F, Trujols J: Feasibility of double-blind clinical trials with oral diacetylmorphine: a randomized controlled phase II study in an inpatient setting. Eur Addict Res 2012;18:279-287.
37.
Gerber H, Borgwardt SJ, Schmid O, Gerhard U, Joechle W, Riecher-Rossler A, Wiesbeck GA, Walter M: The impact of diacetylmorphine on hypothalamic-pituitary-adrenal axis activity and heroin craving in heroin dependence. Eur Addict Res 2012;18:116-123.
38.
Frischknecht U, Beckmann B, Heinrich M, Kniest A, Nakovics H, Kiefer F, Mann K, Hermann D: The vicious circle of perceived stigmatization, depressiveness, anxiety, and low quality of life in substituted heroin addicts. Eur Addict Res 2011;17:241-249.
39.
Pedersen K, Waal H, Kringlen E: Patients with nonaffective psychosis are at increased risk for heroin use disorders. Eur Addict Res 2012;18:124-129.
40.
Torrens M, Rossi PC, Martinez-Riera R, Martinez-Sanvisens D, Bulbena A: Psychiatric co-morbidity and substance use disorders: treatment in parallel systems or in one integrated system? Subst Use Misuse 2012;47:1005-1014.
41.
Bravo MJ, Royuela L, Barrio G, Rodriguez-Arenas MA, De la Fuente L: Prevalence of indirect sharing of drug-injecting paraphernalia in Galicia, Madrid, Seville and Valencia (Spain) (in Spanish). Gac Sanit 2004;18:472-478.
42.
Folch C, Merono M, Casabona J: Factors associated with sharing syringes among street-recruited injecting drug users (in Spanish). Med Clin (Barc) 2006;127:526-532.
43.
Delegación del Gobierno para el Plan Nacional sobre Drogas: Informe del Observatorio Español sobre Drogas (OED). Informe número 6. Noviembre 2003. Madrid, Ministerio del Interior, 2004.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.